A fresh face has joined the board at the US-based biopharmaceutical company Syros Pharmaceuticals in the form of Deborah Dunsire, CEO at Lundbeck, a press release reveals.
"Syros has all the elements for building an enduring company – programs with the potential to set new standards of care for patients, a discovery engine to continue to fuel its pipeline, and great people," Dunsire says in the release, and adds:
Already a subscriber? Log in.
Read the whole article
Get 14 days free access.
No credit card required.
Get full access for you and your coworkers.Start a free company trial today
Your trial for MedWatch has now started
With your free trial you get:
Full access to all locked articles on MedWatch.
Daily newsletter and ongoing top-newsletters. You can unsubscribe and subscribe to our newsletters anytime.
When your trial period expires
You will not be transferred to a paid subscription.
You will continue to receive our newsletters after the trial period expires. You can unsubscribe at the bottom of each newsletter.